Central nervous system (CNS) disorders constitute a growing unmet medical need, with increasing prevalence of aging-related diseases (Alzheimer’s and Parkinson’s). While classical approaches in cell lines and primary neurons are valuable, (patient-derived) stem cell-based neuronal model systems are rapidly developing into established screening tools. In this webinar, we will highlight in vitro models and phenotypic assays to discover and validate novel targets and promising lead molecules.
- Sipke Dijkstra, PhD, Research Fellow, Target Discovery & Validation, Charles River
- Antti Nurmi, PhD, Managing Director, Charles River